Â鶹ӳ»­

MD Anderson researchers develop novel antibody-toxin conjugate

Researchers at MD Anderson have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.

Radiation therapy, the immune system and what¡¯s ahead

Radiation therapy is often thought of as a treatment for localized cancer that hasn¡¯t spread. But when paired with other therapies, it can be an effective option for patients with metastatic disease.

Research presented by Benjamin Schrank, M.D., Ph.D., at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting is offering a new pathway for immunotherapy-driven cancer treatment.